Jasper Therapeutics, Inc. (JSPR), a clinical-stage biotechnology company, on Tuesday reported encouraging preliminary data from its ETESIAN Phase 1b study of subcutaneous briquilimab in adults with allergic asthma.
A single subcutaneous dose of briquilimab led to substantial reductions in sputum eosinophils at six and twelve weeks, along with improvements in FEV1 in both Early Asthmatic Response (EAR) and Late Asthmatic Response (LAR). Significant reductions in serum tryptase were also observed, consistent with findings from other briquilimab studies at the 180mg dose.
Briquilimab was well tolerated, showing a favorable safety profile. The preliminary results support the continued development of briquilimab as a potential treatment for asthma.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.